Property News · December 2, 2022

New Eisai-Biogen Alzheimer’s drug shows plenty of promise in Phase 3 clinical trial


The trial data which shows reduced rate of cognitive decline by 27 percent compared to placebo; further study to be done on side effects

Source : arabianbusiness.com
Read more…New Eisai-Biogen Alzheimer’s drug shows plenty of promise in Phase 3 clinical trial